Stage 8 · ACLS Lab

The drugs

What each drug is, what it does to the cells and receptors of the heart, when the algorithms use it, how much for adults and for children, and what to watch for.

Guidelines: AHA 2020 with the 2023 update and confirmed 2025 changes; PALS 2020 with the 2025 pediatric updates

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline. Pediatric content follows the AHA 2020 PALS algorithms with the 2025 AHA/AAP pediatric updates where confirmed.

Cardiac arrest Pediatric doses

Epinephrine (bolus)

The arrest vasopressor

Class: Catecholamine; alpha- and beta-adrenergic agonist

How it works

In cardiac arrest the alpha-1 effect matters most: it squeezes peripheral arteries, raising aortic diastolic pressure and with it the coronary perfusion pressure that compressions generate. Beta-1 stimulation raises rate and contractility, which helps after ROSC but increases the heart's oxygen demand.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Every pulseless rhythm: VF, pulseless VT, asystole and PEA.
  • Non-shockable rhythms: give it as soon as possible.
  • Shockable rhythms: give it after the initial shocks have failed (in the algorithm, after the second shock).

Dose

UseDose and routeRepeat and maximumSource
Adult Cardiac arrest1 mgIV/IOevery 3–5 minutes; no maximumAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Pediatric Pediatric cardiac arrest, or bradycardia with poor perfusion despite oxygenation and ventilation0.01 mg/kg (0.1 mL/kg of 0.1 mg/mL)IV/IOevery 3–5 minutes; 1 mg per doseAHA 2020 PALS algorithms; 2025 AHA/AAP PALS algorithm

Do not use, or take care

  • No absolute contraindication in cardiac arrest.
  • After ROSC it can provoke tachycardia, ectopy and recurrent VF.
  • Higher (escalating) doses are not recommended: they did not improve survival.
  • Flush each dose; IV is the first-choice route, IO if IV cannot be placed.

What it does to the ECG and the heart

In arrest there is no rhythm change to expect from the drug itself. With a pulse: sinus tachycardia, ectopic beats, and in an ischemic heart ST depression or ventricular arrhythmias.

See: Ventricular fibrillation, coarse, Asystole

Remember

  • Two clocks run in an arrest: the 2-minute CPR cycle and the 3–5-minute epinephrine timer.
  • Vasopressin offers no advantage over epinephrine and is no longer in the algorithm.

Cardiac arrest Pediatric doses

Amiodarone

Antiarrhythmic for shock-refractory VF/pVT and stable VT

Class: Class III antiarrhythmic (also class I, II and IV effects)

How it works

Blocks potassium channels so the action potential lasts longer and the cell stays refractory longer; a re-entrant wave meets tissue it cannot yet excite and dies out. It also blocks sodium and calcium channels and beta-receptors.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • VF or pulseless VT that persists after shocks (with lidocaine as the alternative).
  • Stable regular wide-complex (monomorphic VT) tachycardia, as an infusion.

Dose

UseDose and routeRepeat and maximumSource
Adult Cardiac arrest (VF/pVT), first dose300 mg bolusIV/IOsecond dose 150 mg; two doses in the arrestAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Adult Stable wide-QRS tachycardia150 mg over 10 minutesIVrepeat as needed if VT recurs; then 1 mg/min for the first 6 hoursAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Pediatric Pediatric VF/pVT5 mg/kg bolusIV/IOup to 3 total doses for refractory VF/pVT; 300 mg per doseAHA 2020 PALS cardiac arrest algorithm; 2025 algorithm
Pediatric Pediatric wide-complex tachycardia with a pulse5 mg/kg over 20–60 minutesIV/IO300 mgAHA 2020 PALS tachycardia algorithm

Do not use, or take care

  • With a pulse: cardiogenic shock, marked sinus bradycardia or high-grade AV block without a pacemaker.
  • Hypotension and bradycardia, especially with rapid infusion.
  • Prolongs the QT; avoid combining with other QT-prolonging drugs.
  • Half-life of weeks: effects outlast the resuscitation.

What it does to the ECG and the heart

Slower sinus and AV nodal conduction, a longer QT interval and sometimes a wider QRS.

See: Ventricular fibrillation, coarse, Monomorphic ventricular tachycardia

Remember

  • Arrest dose 300 then 150; stable VT dose 150 over 10 minutes. Same drug, different speeds.

Cardiac arrest Pediatric doses

Lidocaine

The alternative to amiodarone

Class: Class Ib antiarrhythmic (sodium-channel blocker)

How it works

Binds fast sodium channels, mostly in cells that are depolarized and firing fast, such as ischemic tissue. It slows phase 0 there and raises the threshold for re-entry while leaving normal tissue largely alone.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • VF or pulseless VT persisting after shocks, as an alternative to amiodarone.
  • May be considered after ROSC from VF/pVT to prevent recurrence.

Dose

UseDose and routeRepeat and maximumSource
Adult Cardiac arrest (VF/pVT)1–1.5 mg/kg first doseIV/IO0.5–0.75 mg/kg; 3 mg/kg in totalAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Pediatric Pediatric VF/pVT1 mg/kg loading doseIV/IO—AHA 2020 PALS cardiac arrest algorithm; 2025 algorithm

Do not use, or take care

  • High-grade AV block or a slow escape rhythm: it can suppress the escape focus.
  • Toxicity is neurological first: perioral numbness, confusion, seizures.
  • Accumulates in heart failure and liver disease.

What it does to the ECG and the heart

Little change at therapeutic doses; toxicity can cause bradycardia and a wider QRS.

See: Ventricular fibrillation, coarse

Remember

  • Pick amiodarone or lidocaine; there is no evidence that one beats the other for survival to discharge.

Cardiac arrest

Magnesium sulfate

For torsades de pointes

Class: Electrolyte; calcium-channel modulator

How it works

Suppresses the early afterdepolarizations (extra upstrokes during phase 2–3) that trigger torsades when the QT is long, probably by damping L-type calcium current.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Polymorphic VT with a long QT (torsades de pointes).
  • Not for routine use in VF/pVT without torsades.

Dose

UseDose and routeRepeat and maximumSource
Adult Torsades de pointes1–2 gIV/IO, dilutedgiven over minutes in arrest; more slowly with a pulseAHA ACLS teaching (2010–2020 guidance); the 2025 text does not change itOwner to check: Confirm the infusion time for a patient with a pulse against local protocol.

Do not use, or take care

  • Hypermagnesemia; caution in renal failure.
  • Rapid injection causes flushing, hypotension and bradycardia.
  • In pregnancy, a magnesium infusion running at arrest should be stopped (toxicity can cause it).

What it does to the ECG and the heart

Fewer early afterdepolarizations: the torsades stops, though the QT may stay long.

See: Torsades de pointes

Remember

  • A torsades patient without a pulse is defibrillated first; magnesium is the add-on.

Bradycardia Pediatric doses

Atropine

First drug for symptomatic bradycardia

Class: Antimuscarinic (parasympatholytic)

How it works

Blocks M2 muscarinic receptors on the sinus and AV nodes, cutting off the vagal brake. Pacemaker cells drift to threshold faster and the AV node conducts faster. It cannot help tissue the vagus does not reach, such as the His–Purkinje system.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Symptomatic sinus bradycardia.
  • AV block at the level of the node (first degree, Mobitz I).

Dose

UseDose and routeRepeat and maximumSource
Adult Symptomatic bradycardia1 mg bolusIVevery 3–5 minutes; 3 mg totalAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Pediatric Pediatric bradycardia from increased vagal tone or primary AV block0.02 mg/kgIV/IOmay repeat once; 0.5 mg single doseAHA 2020 PALS bradycardia algorithmOwner to check: 2020 printed a 0.1 mg minimum dose; confirm against the 2025 PALS text.

Do not use, or take care

  • Do not let it delay pacing in Mobitz II or third-degree block with a wide escape rhythm.
  • No longer part of the arrest algorithm (asystole, PEA).
  • Unlikely to work after heart transplant (no vagal innervation).
  • Raises oxygen demand: use with care in acute ischemia.

What it does to the ECG and the heart

Faster sinus rate and shorter PR. In infranodal block the ventricular escape rate stays the same; the atrial rate may rise and the block may even worsen.

See: Sinus bradycardia, Third-degree AV block, ventricular escape

Remember

  • Atropine works where the vagus works: above the His bundle.

Bradycardia

Dopamine infusion

Chronotrope and pressor

Class: Catecholamine; dose-dependent dopaminergic, beta-1 and alpha-1 agonist

How it works

At the doses used in ACLS it stimulates beta-1 receptors (rate and contractility) and, as the dose rises, alpha-1 receptors (vasoconstriction).

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Symptomatic bradycardia when atropine is ineffective (an alternative to pacing).
  • Hypotension after ROSC.

Dose

UseDose and routeRepeat and maximumSource
Adult Bradycardia5–20 mcg/kg per minuteIV infusiontitrate to response; taper slowlyAHA 2020 and 2025 bradycardia algorithms (lower limit 5)

Do not use, or take care

  • Uncorrected hypovolemia.
  • Tachyarrhythmias.
  • Tissue necrosis if it extravasates.

What it does to the ECG and the heart

Faster rate; ectopy and tachyarrhythmias at higher doses.

See: Sinus bradycardia

Remember

  • Correct volume first: pressors cannot squeeze an empty tank.

Bradycardia Pediatric doses

Epinephrine infusion

Chronotrope and pressor by infusion

Class: Catecholamine; alpha- and beta-adrenergic agonist

How it works

At low infusion rates beta-1 effects dominate (rate and contractility); higher rates add alpha-1 vasoconstriction.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Symptomatic bradycardia when atropine is ineffective.
  • Hypotension or shock after ROSC.

Dose

UseDose and routeRepeat and maximumSource
Adult Bradycardia2–10 mcg per minuteIV infusiontitrate to responseAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Adult Hypotension after ROSCTitrated infusion to a MAP of at least 65 mm HgIV infusion—AHA 2025 post-cardiac arrest care algorithmOwner to check: The 2020 algorithm printed 0.1–0.5 mcg/kg/min; confirm the range the owner wants shown.
Pediatric Pediatric bradycardia or shock0.1–1 mcg/kg per minute, titratedIV/IO infusion—AHA PALS teaching (2020 provider materials)Owner to check: Septic-shock starting ranges vary; confirm the range the owner wants shown.

Do not use, or take care

  • Not a substitute for fluid in hypovolemia.
  • Tachyarrhythmias and myocardial ischemia.
  • Never give the 1 mg arrest bolus to a patient with a pulse.

What it does to the ECG and the heart

Sinus tachycardia, ectopy.

See: Sinus bradycardia

Remember

  • Micrograms per minute for an infusion, milligrams for the arrest bolus: a thousandfold difference.

Tachycardia Pediatric doses

Adenosine

Momentary AV block

Class: Purine nucleoside; A1-receptor agonist

How it works

Activates A1 receptors in the AV node, which opens potassium channels and cuts cyclic AMP. Nodal cells hyperpolarize and stop conducting for a few seconds. A re-entry circuit that runs through the AV node is broken; other rhythms simply slow briefly and show what is underneath.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Stable regular narrow-complex tachycardia (after vagal maneuvers).
  • Regular narrow tachycardia while preparing to cardiovert, if unstable.
  • Stable regular monomorphic wide-complex tachycardia, as a diagnostic and possible treatment.

Dose

UseDose and routeRepeat and maximumSource
Adult Regular tachycardia6 mg rapid push, then a saline flushIV12 mg if needed; two doses in the algorithmAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Pediatric Pediatric SVT0.1 mg/kg rapid push (max 6 mg)IV/IO0.2 mg/kg (max 12 mg)AHA 2020 PALS tachycardia algorithm

Do not use, or take care

  • Irregular or polymorphic wide-complex tachycardia (pre-excited AF may accelerate).
  • Second- or third-degree AV block or sick sinus syndrome without a pacemaker.
  • Caution in reactive airway disease.
  • Half-life under 10 seconds: push fast, close to the heart, and flush.
  • Lower doses for heart transplant, central-line injection, or patients on dipyridamole or carbamazepine; theophylline and caffeine blunt it.
  • Warn the patient: a brief sense of doom, chest tightness and flushing are expected.

What it does to the ECG and the heart

A few seconds of high-grade AV block or asystole, then either sinus rhythm (re-entry broken) or the same tachycardia with flutter waves or atrial activity revealed.

See: AV nodal re-entrant tachycardia (AVNRT), Atrial flutter, 2:1 conduction

Remember

  • Record a rhythm strip while you push it: the pause is diagnostic.

Tachycardia Pediatric doses

Procainamide

For stable wide-complex tachycardia

Class: Class Ia antiarrhythmic (sodium- and potassium-channel blocker)

How it works

Slows phase 0 (sodium block) and lengthens repolarization (potassium block), slowing conduction and extending refractoriness in atria, ventricles and accessory pathways.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Stable regular wide-complex tachycardia.
  • Pre-excited atrial fibrillation (it slows the accessory pathway).

Dose

UseDose and routeRepeat and maximumSource
Adult Stable wide-QRS tachycardia20–50 mg/minIV infusionuntil the arrhythmia stops, hypotension develops, the QRS widens by more than 50% or 17 mg/kg has been given; 17 mg/kg; maintenance 1–4 mg/minAHA 2020 adult algorithm; unchanged in the 2025 algorithm
Pediatric Pediatric wide-complex tachycardia with a pulse15 mg/kg over 30–60 minutesIV/IOdo not routinely combine with amiodaroneAHA 2020 PALS tachycardia algorithm

Do not use, or take care

  • Prolonged QT.
  • Heart failure.
  • Hypotension.
  • Do not combine with amiodarone without expert advice.

What it does to the ECG and the heart

Wider QRS and longer QT: stop when the QRS has widened by half.

See: Monomorphic ventricular tachycardia, Pre-excited atrial fibrillation (AF with WPW)

Remember

  • The stopping rules are part of the dose.

Tachycardia

Sotalol

Removed from the 2025 tachycardia algorithm

Class: Class III antiarrhythmic with beta-blockade

How it works

Blocks potassium channels (longer action potential and refractory period) and beta-receptors.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Listed in the 2020 algorithm for stable wide-complex tachycardia; the 2025 algorithm no longer lists it.

Dose

UseDose and routeRepeat and maximumSource
Adult Stable wide-QRS tachycardia (2020 algorithm)100 mg (1.5 mg/kg) over 5 minutesIV—AHA 2020 tachycardia algorithm; removed from the AHA 2025 algorithmOwner to check: Removal reported in the 2025 interim provider materials; confirm before publishing.

Do not use, or take care

  • Prolonged QT.
  • Torsades de pointes; bradycardia; hypotension.

What it does to the ECG and the heart

Longer QT; slower sinus rate.

See: Monomorphic ventricular tachycardia

Remember

  • Shown here for completeness: the current algorithm uses procainamide or amiodarone.

Tachycardia

Beta-blockers (metoprolol, esmolol)

Rate control for narrow-complex tachycardia

Class: Class II antiarrhythmics; beta-1 antagonists

How it works

Block beta-1 receptors on nodal cells, flattening the phase 4 slope and slowing AV conduction, so the ventricular rate falls.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Stable narrow-complex tachycardia not converted by vagal maneuvers or adenosine.
  • Rate control in atrial fibrillation or flutter.

Dose

UseDose and routeRepeat and maximumSource
Adult Metoprolol5 mg over 1–2 minutesIVevery 5 minutes; 15 mgAHA ACLS teaching (2020 provider materials)Owner to check: Not printed on the 2025 algorithm; confirm against local protocol.
Adult Esmolol500 mcg/kg over 1 minute, then 50 mcg/kg/minIVtitrateAHA ACLS teaching (2020 provider materials)Owner to check: Not printed on the 2025 algorithm; confirm against local protocol.

Do not use, or take care

  • Hypotension, decompensated heart failure or shock.
  • Pre-excited AF, second- or third-degree block.
  • Caution in bronchospastic disease.
  • Additive with calcium-channel blockers: profound bradycardia and hypotension.

What it does to the ECG and the heart

Slower sinus and ventricular rates; longer PR.

See: Atrial fibrillation with rapid ventricular response

Remember

  • Rate control, not rhythm control.

Tachycardia

Diltiazem and verapamil

Calcium-channel blockers for narrow tachycardia

Class: Class IV antiarrhythmics; non-dihydropyridine calcium-channel blockers

How it works

Block L-type calcium channels, which carry the upstroke (phase 0) in sinus and AV nodal cells. Nodal conduction slows, re-entry through the node can stop, and the ventricular response to AF or flutter falls.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Stable narrow-complex tachycardia after vagal maneuvers and adenosine.
  • Rate control in atrial fibrillation or flutter.

Dose

UseDose and routeRepeat and maximumSource
Adult Diltiazem15–20 mg (0.25 mg/kg) over 2 minutesIV20–25 mg (0.35 mg/kg) after 15 minutes if needed; maintenance 5–15 mg/hAHA ACLS teaching (2020 provider materials)Owner to check: Not printed on the 2025 algorithm; confirm against local protocol.
Adult Verapamil2.5–5 mg over 2 minutesIV5–10 mg every 15–30 minutes; 20 mgAHA ACLS teaching (2020 provider materials)Owner to check: Not printed on the 2025 algorithm; confirm against local protocol.

Do not use, or take care

  • Wide-complex tachycardia unless certainly supraventricular: in VT they can cause collapse.
  • Pre-excited AF (WPW).
  • Hypotension, heart failure with reduced ejection fraction.
  • Hypotension; additive with beta-blockers.

What it does to the ECG and the heart

Slower ventricular rate in AF and flutter; a longer PR.

See: Atrial fibrillation with rapid ventricular response, AV nodal re-entrant tachycardia (AVNRT)

Remember

  • Never for a wide-complex tachycardia you are not sure about.

Blood pressure and post-ROSC Pediatric doses

Isotonic crystalloid (fluid bolus)

Volume for hypovolemia and shock

Class: Isotonic crystalloid (balanced solution or normal saline)

How it works

Restores circulating volume, so more blood returns to the heart, stretches it, and is pumped out (preload, then stroke volume). It cannot help a heart that is already full or failing; too much causes pulmonary edema.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Hypovolemia and hemorrhage (with blood products).
  • Septic shock in children: boluses with reassessment after each.
  • Post-ROSC hypotension when under-filled.

Dose

UseDose and routeRepeat and maximumSource
Adult AdultsBolus, often 500–1000 mL, reassessing after eachIV/IO—AHA ACLS teaching; AHA 2025 post-cardiac arrest care (fluids for hypotension)Owner to check: No single adult bolus volume is printed in the algorithms.
Pediatric Children: shock10–20 mL/kgIV/IOreassess after each bolus (perfusion, liver edge, crackles); stop if signs of fluid overload; 5–10 mL/kg if cardiac dysfunctionAHA 2020 PALS (10 or 20 mL/kg aliquots with reassessment); 2025 PALS course materials

Do not use, or take care

  • Signs of fluid overload: crackles, hepatomegaly, rising work of breathing.
  • Reassess after every bolus.
  • Cardiogenic shock needs smaller, slower boluses and early inotropes.

What it does to the ECG and the heart

Sinus tachycardia slows as volume is restored.

See: Sinus tachycardia

Remember

  • Push, then look: perfusion, heart rate, blood pressure, liver edge, lungs.

Blood pressure and post-ROSC Pediatric doses

Norepinephrine

Vasopressor after ROSC

Class: Catecholamine; mainly alpha-1 with some beta-1 agonism

How it works

Constricts arterioles (alpha-1) to raise mean arterial pressure, with a modest increase in contractility (beta-1) and little effect on rate.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Hypotension or shock after ROSC that persists after fluids.

Dose

UseDose and routeRepeat and maximumSource
Adult Hypotension after ROSCTitrated infusion to a MAP of at least 65 mm HgIV infusion—AHA 2025 post-cardiac arrest care algorithmOwner to check: The 2020 algorithm printed 0.1–0.5 mcg/kg/min; confirm the range the owner wants shown.
Pediatric Pediatric fluid-refractory septic shock0.05–2 mcg/kg per minute, titratedIV/IO infusion—AHA 2020 PALS (epinephrine or norepinephrine as first vasoactive in fluid-refractory septic shock)Owner to check: Range from 2025 course materials; confirm.

Do not use, or take care

  • Uncorrected hypovolemia.
  • Extravasation injury; peripheral ischemia at high doses.

What it does to the ECG and the heart

Little direct effect; reflex slowing of the rate is possible.

Remember

  • Target a MAP of 65 mm Hg or more after ROSC; hypotension worsens brain injury.

Special circumstances

Calcium chloride and gluconate

For hyperkalemia and calcium-channel blocker toxicity

Class: Electrolyte; membrane stabilizer

How it works

In hyperkalemia the resting potential creeps toward threshold. Extra calcium raises the threshold back, restoring the gap between rest and firing, within minutes. It does not lower the potassium.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Hyperkalemia with ECG changes or arrest.
  • Calcium-channel blocker overdose.
  • Magnesium toxicity (for example in pregnancy).
  • Not for routine use in cardiac arrest.

Dose

UseDose and routeRepeat and maximumSource
Adult Calcium chloride 10%500–1000 mg (5–10 mL)IV/IOrepeat as neededAHA ACLS teaching; the 2025 guidelines keep it for specific causes onlyOwner to check: Confirm doses against local protocol.
Adult Calcium gluconate 10%1.5–3 g (15–30 mL)IV/IOrepeat as neededAHA ACLS teaching; the 2025 guidelines keep it for specific causes onlyOwner to check: Confirm doses against local protocol.

Do not use, or take care

  • Digoxin toxicity (relative).
  • Never in the same line as sodium bicarbonate (precipitates).
  • Calcium chloride irritates veins: prefer a large or central vein.

What it does to the ECG and the heart

In hyperkalemia: a narrower QRS and a return of the P wave within minutes; peaked T waves may persist.

Remember

  • Calcium protects the heart; insulin, glucose and bicarbonate move the potassium.

Special circumstances

Sodium bicarbonate

For specific causes, not routine

Class: Alkalinizing agent; sodium load

How it works

Raises pH, which shifts potassium into cells, and loads sodium, which overcomes sodium-channel blockade by tricyclic antidepressants and similar drugs.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Hyperkalemia.
  • Tricyclic or other sodium-channel blocker overdose with a wide QRS.
  • Pre-existing severe metabolic acidosis.
  • Not for routine use in cardiac arrest.

Dose

UseDose and routeRepeat and maximumSource
Adult Specific causes1 mEq/kgIV/IOguided by the cause and the blood gasAHA ACLS teaching; the 2025 guidelines do not recommend routine useOwner to check: Confirm against local protocol.

Do not use, or take care

  • Routine use in arrest without one of the causes above.
  • Produces CO₂, which can worsen intracellular acidosis if ventilation is poor.
  • Hypernatremia; inactivates catecholamines and precipitates calcium in the same line.

What it does to the ECG and the heart

In sodium-channel blocker toxicity: the QRS narrows and the terminal R in aVR shrinks.

Remember

  • Treat a cause, not a number.

Special circumstances

Glucagon

For beta-blocker (and calcium-channel blocker) toxicity

Class: Peptide hormone; raises cAMP without the beta receptor

How it works

Glucagon acts on its own receptor on cardiac cells, which raises cAMP just as beta stimulation would. A beta-blocker cannot block it, so it can restore some rate and contractility when the beta receptors are occupied.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Symptomatic bradycardia and hypotension from beta-blocker overdose.
  • Sometimes tried in calcium-channel blocker overdose; calcium and high-dose insulin matter more there.

Dose

UseDose and routeRepeat and maximumSource
Adult Beta-blocker toxicity3–10 mg IV over 3–5 minutes (about 0.05–0.15 mg/kg)IVthen an infusion of 3–5 mg/h if it helpsAHA 2023 focused update on the management of patients with cardiac arrest or life-threatening toxicity due to poisoningOwner to check: Owner to check the bolus range and infusion rate against the 2023 toxicology update.

Do not use, or take care

  • Pheochromocytoma (can release catecholamines).
  • Vomiting is common: protect the airway.
  • Raises blood glucose; the effect wears off within minutes, so an infusion follows a response.

What it does to the ECG and the heart

A faster sinus or escape rate and better conduction if it works; often a modest effect.

See: Sinus bradycardia, Junctional escape rhythm

Remember

  • High-dose insulin, calcium and vasopressors are given alongside, not instead.

Bradycardia

Isoproterenol infusion

A pure beta agonist that speeds the heart

Class: Catecholamine; beta-1 and beta-2 agonist

How it works

Stimulates beta-1 receptors (faster rate, faster conduction) and beta-2 receptors (vasodilation). A faster heart rate shortens the QT, which is why it can stop pause-dependent torsades from recurring.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Recurrent pause-dependent torsades de pointes with an acquired long QT, as a bridge to overdrive pacing.
  • Symptomatic bradycardia unresponsive to atropine, where it is available (a second-line chronotrope).

Dose

UseDose and routeRepeat and maximumSource
Adult Infusion2–10 mcg/min, titrated to the heart rateIV—AHA ACLS teaching on bradycardia and torsades de pointesOwner to check: Owner to check: confirm the infusion range and its place in the 2025 bradycardia text.

Do not use, or take care

  • Congenital long QT syndrome (adrenergic triggers make it worse).
  • Active ischemia: it raises oxygen demand.
  • Vasodilation can lower the blood pressure.
  • Can provoke ventricular arrhythmias.

What it does to the ECG and the heart

A faster sinus rate and a shorter QT.

See: Torsades de pointes

Remember

  • For torsades that keeps coming back after magnesium: raise the rate, with isoproterenol or overdrive pacing.

Special circumstances

Naloxone

Reverses opioid respiratory depression

Class: Opioid receptor antagonist

How it works

Displaces opioids from mu receptors in the brainstem respiratory centre, restoring the drive to breathe. It does nothing for a heart that has stopped: the arrest itself is treated with CPR.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Suspected opioid overdose with respiratory depression or respiratory arrest and a pulse.
  • In opioid-associated cardiac arrest it may be given, but never in place of CPR.

Dose

UseDose and routeRepeat and maximumSource
Adult Intranasal4 mgINevery 2–3 minutes if no responseAHA 2020 opioid-associated emergency algorithms; 2025 guidelines endorse naloxoneOwner to check: Confirm current product strengths against local protocol.
Adult Intramuscular or intravenous0.4 mg, titratedIM/IVevery 2–3 minutes; up to 2 mg per doseAHA 2020 opioid-associated emergency algorithms; 2025 guidelines endorse naloxoneOwner to check: Confirm current product strengths against local protocol.

Do not use, or take care

  • None in a life-threatening overdose.
  • Acute withdrawal in dependent patients: agitation, vomiting, pulmonary edema.
  • Shorter acting than many opioids: watch for re-sedation.

What it does to the ECG and the heart

No direct effect; correcting hypoxia may resolve bradycardia or ectopy.

Remember

  • Ventilate first. Oxygen and a bag-mask buy time naloxone cannot.

Special circumstances Pediatric doses

Oxygen

A drug with targets

Class: Medical gas

How it works

Raises arterial oxygen content. In arrest, deliver the highest concentration available; once there is circulation, too much is harmful too, so titrate to a target.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • During CPR: 100%.
  • After ROSC: titrate to an SpO₂ of 90–98%.
  • ACS: only if SpO₂ is below 90%.
  • Bradycardia and tachycardia: if hypoxemic.

Dose

UseDose and routeRepeat and maximumSource
Adult After ROSCTitrate to SpO₂ 90–98%inhaled—AHA 2025 post-cardiac arrest care algorithm
Adult Acute coronary syndromesOnly if SpO₂ < 90%inhaled—ACC/AHA 2025 acute coronary syndromes guideline (as taught in ACLS)
Pediatric Children after ROSCNormoxemia: SpO₂ 94–99%inhaled—AHA 2020 PALS post-cardiac arrest careOwner to check: Confirm the 2025 PALS post-arrest SpO₂ target.

Do not use, or take care

  • None in hypoxemia.
  • Hyperoxia after ROSC is associated with worse outcomes.

What it does to the ECG and the heart

None directly; hypoxia drives bradycardia and ectopy.

Remember

  • Give 100% until you can measure, then titrate.

ACS and stroke

Aspirin

The first drug for ACS

Class: Antiplatelet (irreversible COX-1 inhibitor)

How it works

Blocks thromboxane A2 production in platelets for their whole lifespan, so fewer platelets join the thrombus forming on a ruptured plaque.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Suspected acute coronary syndrome, as early as possible.

Dose

UseDose and routeRepeat and maximumSource
Adult Suspected ACS162–325 mg, chewed (non-enteric-coated)oral—ACC/AHA 2025 acute coronary syndromes guideline; AHA ACLS ACS teachingOwner to check: Confirm the dose range the owner wants shown.

Do not use, or take care

  • True aspirin allergy.
  • Active gastrointestinal bleeding.
  • Chewing speeds absorption.

What it does to the ECG and the heart

None.

Remember

  • Chew it: a swallowed coated tablet takes far longer to work.

ACS and stroke

Nitroglycerin

Preload reduction for ischemic pain

Class: Nitrate vasodilator

How it works

Releases nitric oxide, which relaxes venous smooth muscle more than arterial: venous return (preload) falls, so wall stress and oxygen demand fall. It also dilates coronary arteries.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Ongoing ischemic chest discomfort with an adequate blood pressure.
  • Hypertension or pulmonary edema with ACS.

Dose

UseDose and routeRepeat and maximumSource
Adult Ischemic chest discomfort0.4 mg sublingualSLevery 5 minutes; 3 doses, then consider IVAHA ACLS ACS teaching; ACC/AHA 2025 ACS guidelineOwner to check: Confirm against local protocol.

Do not use, or take care

  • Systolic BP below 90 mm Hg (or 30 mm Hg or more below baseline).
  • Right ventricular infarction (preload dependent).
  • A phosphodiesterase-5 inhibitor in the last 24 hours (48 hours for tadalafil).
  • Hypotension, headache.

What it does to the ECG and the heart

None directly; relief of ischemia may resolve ST depression.

Remember

  • Inferior STEMI? Look at V4R before giving nitrates.

ACS and stroke

Morphine and fentanyl

Analgesia only when nitrates fail

Class: Opioid analgesics

How it works

Mu-receptor agonists: they relieve pain and anxiety and reduce sympathetic drive. Morphine also dilates veins.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • Chest pain in ACS that persists despite nitrates.

Dose

UseDose and routeRepeat and maximumSource
Adult Refractory ischemic painSmall titrated IV dosesIV—ACC/AHA 2025 acute coronary syndromes guideline; AHA ACLS ACS teachingOwner to check: No dose shown on purpose; set one only if the owner wants it.

Do not use, or take care

  • Hypotension, respiratory depression.
  • Morphine slows the absorption of oral P2Y12 inhibitors such as ticagrelor and clopidogrel.
  • Masks ongoing ischemia: pain relief is not reperfusion.

What it does to the ECG and the heart

None directly.

Remember

  • Analgesia is a comfort measure, not a treatment for the occlusion.

ACS and stroke

Fibrinolytics (alteplase, tenecteplase, reteplase)

Dissolve the clot when PCI or thrombectomy is too far away

Class: Plasminogen activators

How it works

Convert plasminogen to plasmin, which cuts the fibrin mesh holding a thrombus together and reopens the artery. They cannot tell a coronary clot from one that is sealing a vessel elsewhere, which is why bleeding is the main risk.

A picture of the mechanism appears here with JavaScript on.

When it is used

  • STEMI within 12 hours of onset when primary PCI cannot be done within 120 minutes of first medical contact: door-to-needle within 30 minutes.
  • Acute ischemic stroke within 4.5 hours of last known well, with no hemorrhage on imaging.
  • Cardiac arrest from confirmed (or strongly suspected) pulmonary embolism.

Dose

UseDose and routeRepeat and maximumSource
Adult Stroke: alteplase0.9 mg/kg (max 90 mg): 10% as a bolus over 1 minute, the rest over 60 minutesIV—AHA/ASA acute ischemic stroke guidelines (2019, 2026), as taught in AHA 2020 ACLSOwner to check: Confirm against the 2026 AHA/ASA guideline text.
Adult Stroke: tenecteplase0.25 mg/kg (max 25 mg) single bolusIV—AHA/ASA 2026 acute ischemic stroke guideline (as reported)Owner to check: Confirm against the 2026 AHA/ASA guideline text.
Adult STEMIAgent-specific weight-based regimensIV—ACC/AHA 2025 acute coronary syndromes guidelineOwner to check: Doses vary by agent; none shown on purpose.
Adult Cardiac arrest from pulmonary embolismAlteplase 50 mg IV bolus (a commonly used regimen); continue CPR for 60–90 minutes after itIV—AHA 2020/2025 ACLS: thrombolysis is reasonable for confirmed PE causing arrest and may be considered when PE is suspected; the guidelines name no doseOwner to check: Owner to check: the 50 mg bolus and the 60–90 minute CPR window are common practice, not an AHA-specified regimen.

Do not use, or take care

  • Any prior intracranial hemorrhage; known cerebral vascular lesion or intracranial tumour.
  • Active bleeding or bleeding diathesis; suspected aortic dissection.
  • Significant head trauma or intracranial or spinal surgery recently.
  • Stroke: blood pressure above 185/110 mm Hg that cannot be lowered before treatment.
  • After stroke thrombolysis keep BP at or below 180/105 mm Hg for 24 hours.
  • Watch for angioedema and neurological worsening (bleeding).

What it does to the ECG and the heart

After STEMI lysis: ST resolution of 50% or more and reperfusion arrhythmias (accelerated idioventricular rhythm) suggest the artery has opened.

See: Accelerated idioventricular rhythm

Remember

  • Time is muscle, and time is brain: the clock starts at symptom onset.

No longer recommended

Practices from older courses that the current guidelines have dropped.

PracticeWhy it went
Vasopressin in place of, or with, epinephrineNo survival advantage; removed from the arrest algorithm in 2015.
Atropine for asystole or PEANo benefit; removed in 2010. Atropine is a bradycardia drug.
Routine calcium in cardiac arrestNo benefit and possible harm; keep it for hyperkalemia, calcium-channel blocker toxicity and hypermagnesemia.
Routine sodium bicarbonate in cardiac arrestNo benefit; keep it for hyperkalemia, sodium-channel blocker toxicity and pre-existing acidosis.
Routine magnesium for VF/pVTOnly for torsades de pointes with a long QT.
High-dose epinephrineEscalating doses did not improve survival.
Transcutaneous pacing for asystoleDoes not improve outcome in cardiac arrest.
Sotalol in the tachycardia algorithmNo longer listed in the 2025 algorithm (procainamide or amiodarone remain).

Guidelines and sources

Reflects the AHA 2020 adult algorithms with the 2023 focused update, updated for the 2025 AHA Guidelines for CPR and ECC where the change could be confirmed; acute coronary syndromes follow the 2025 ACC/AHA guideline and stroke the 2026 AHA/ASA guideline.

Algorithms and doses follow the AHA 2020 Guidelines for CPR and ECC, adult algorithms (Part 3: Adult Basic and Advanced Life Support, Circulation 2020;142(suppl 2):S366–S468), checked for changes in:

  • 2023 AHA Focused Update on Adult Advanced Cardiovascular Life Support (Circulation 2024;149:e254–e273)
  • 2025 AHA Guidelines for CPR and ECC, Part 9: Adult Advanced Life Support

Changes in the 2025 guidelines reflected here:

  • Synchronized cardioversion of atrial fibrillation: an initial energy of at least 200 J with a biphasic defibrillator is now recommended, rather than a lower first shock.
  • The tachycardia algorithm refers to the device's recommended energy level rather than listing energies for each rhythm.
  • Intravenous access is preferred to intraosseous access as the first attempt in cardiac arrest.
  • Double sequential defibrillation and vector-change defibrillation for refractory VF remain of uncertain benefit.
  • Sotalol is no longer listed in the tachycardia algorithm; procainamide and amiodarone remain.
  • Routine calcium and sodium bicarbonate are not recommended in cardiac arrest; both are kept for specific causes.
  • After ROSC: titrate oxygen to an SpO₂ of 90–98%, keep the MAP at 65 mm Hg or more, and use deliberate temperature control (32–37.5 °C) for patients not following commands.
  • Polymorphic VT is treated as unstable and defibrillated.

Sources:

  1. Panchal AR, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16 suppl 2):S366–S468.
  2. Perman SM, et al. 2023 American Heart Association Focused Update on Adult Advanced Cardiovascular Life Support. Circulation. 2024;149:e254–e273.
  3. Lavonas EJ, et al. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning. Circulation. 2023;148:e149–e184.
  4. Part 7: Adult Basic Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  5. Part 9: Adult Advanced Life Support. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2):S538–S577.
  6. Part 10: Adult and Pediatric Special Circumstances of Resuscitation. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  7. Part 11: Post–Cardiac Arrest Care. 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16 suppl 2).
  8. Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151(13):e771–e862.
  9. Prabhakaran S, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke (AHA/ASA). Stroke. 2026. doi:10.1161/STR.0000000000000513.

The full 2025 guideline text could not be opened when this page was drafted; the 2025 changes listed were confirmed from summaries of AHA's published 2025 algorithms and highlights. Drug doses are the 2020 algorithm doses, which those 2025 algorithms keep. All text and pictures here are original teaching material, not reproductions of AHA algorithms. Education only, not a treatment protocol.